To this end, small inhibitors targeting HIF2α, but not HIF1α, have been developed to repress ccRCC growth and already underwent clinical trial waiting for FDA approval for ccRCC therapies [13–15]. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.